An Epilepsy Drug Might Fix Osteoarthritis Cartilage, Yale Study Finds

💡 Yale researchers found that lacosamide, an FDA-approved epilepsy drug, blocks a protein called Nav1.7 that simultaneously drives joint pain and cartilage destruction in osteoarthritis. In preclinical tests, monthly joint injections not only quieted pain but also stimulated cartilage repair, suggesting it could be the first disease-modifying OA treatment.

Why every current OA treatment falls short

Osteoarthritis is not just inflammation. The cartilage cushioning the ends of your bones gradually wears down, and once it goes, it does not come back on its own. Osteoarthritis affects about 500 million people globally: roughly 1 in 8 adults worldwide carries the diagnosis. In the United States alone that is around 32 million people, and the number rises sharply with age.

The core problem with every current FDA-approved treatment for OA is this: they address the symptom (pain) but do nothing to the underlying tissue loss. NSAIDs, corticosteroid injections, and hyaluronic acid shots can reduce pain for weeks or months. None slows the cartilage destruction. That is why joint replacement surgery remains the endpoint for severe OA. This gap is exactly what makes the Yale finding worth attention.

What does Nav1.7 have to do with joint pain and cartilage damage?

Nav1.7 is a sodium channel protein best known for its role in pain transmission. It sits in peripheral nerve fibers and helps carry pain signals toward the brain. Inherited mutations in the gene that encodes Nav1.7 are associated with rare conditions where people feel no pain at all, which makes the channel an attractive target for pain research.

What the Yale team, led by Dr. Chuan-Ju Liu at Yale School of Medicine, discovered is a less obvious role: Nav1.7 also becomes overactive in chondrocytes, the specialized cells that maintain cartilage. When Nav1.7 fires excessively in these cells, it pushes them from a repair mode into a destruction mode. They ramp up production of matrix-degrading enzymes and reduce production of the structural proteins that keep cartilage intact. Block Nav1.7, and you reverse both effects: pain signaling quiets, and two repair-associated proteins, HSP70 and midkine, increase. One molecular target, two payoffs, in a joint where those payoffs have never existed together before.

Nav1.7's dual role in nerve pain and joint tissue biology puts it in a growing category of proteins where nerve signals and tissue maintenance are more entangled than textbooks have traditionally shown.

What did Yale's preclinical tests actually show?

The team published in Bioactive Materials (October 2026), testing lacosamide in a rat model of osteoarthritis. Lacosamide is already on pharmacy shelves as an FDA-approved epilepsy drug, which is what makes this a drug-repurposing story rather than a new-molecule story.

The key findings were:

• Lacosamide reduced pain markers and slowed cartilage breakdown in the animal model.
• It also stimulated cartilage-protective protein production, a repair signal not seen with current OA drugs.
• Dose precision mattered: the optimal effect appeared at a specific low concentration. Higher doses diminished the cartilage benefit, which means the system is finely tuned and delivery method matters.
• Monthly joint injections via a slow-release hydrogel outperformed daily oral dosing for cartilage protection.

The hydrogel, made from Type II collagen (the predominant protein in cartilage), remains liquid in a cool syringe and solidifies at body temperature, forming a local reservoir that releases lacosamide gradually over several weeks. The researchers compare it to a controlled-release pill, but placed directly inside the joint.

What does this mean if you have osteoarthritis?

This is the section that matters most, and the honest answer has two parts.

First, the genuine signal: if these results hold in human joints, lacosamide could be the first treatment to simultaneously reduce pain and prevent the cartilage loss that leads to replacement surgery. The fact that the drug is already FDA-approved for another condition is a real advantage. Drug-repurposing studies skip the early safety phases, which shorten the path to an OA-specific clinical trial by years.

For those already living with OA pain, this matters because current options involve a tradeoff: pain relief now, with no effect on the joint's underlying trajectory. A drug that addresses both would change the clinical calculus for when to intervene, how often to inject, and whether surgery can be delayed or avoided entirely.

Second, the honest check: you are not close to receiving this at a clinic. These results come from rats. Whether human cartilage responds the same way, at the same dose, with the same hydrogel formulation, is unknown. The work is promising enough to justify a Phase 1 safety trial, but that trial has not started yet.

It is also worth noting how this connects to a broader frontier in biology: the idea that damaged tissue can be instructed to repair itself rather than simply being managed with painkillers. Research on cells that survive programmed death to trigger repair is part of the same emerging picture.

Why local delivery matters: joint injection vs daily pill

One result from the study deserves its own explanation. Why did a monthly injection beat a daily pill? The knee joint is a relatively sealed space, but it clears injected fluids quickly through the synovial membrane. Most intra-articular drugs wear off within days. That clearance problem is partly why current corticosteroid injections are limited to a few per year: each injection causes some damage, so frequent dosing is self-defeating.

The thermoresponsive collagen hydrogel solves this by converting a one-time injection into a depot that releases drug slowly over weeks. Monthly dosing intervals are clinically practical (comparable to some existing biologics) and avoids the systemic exposure that comes with daily oral lacosamide at epilepsy-relevant doses. Systemic exposure matters because the drug's effects are dose-sensitive: the therapeutic window for cartilage repair is narrow, and higher systemic concentrations could negate it.

What can't this research tell us yet?

To be specific about what is known and what is not:

• All results are from an animal model. Rat cartilage is structurally similar to human cartilage in some ways, but differs in cell density, loading patterns, and disease progression timelines.
• There is no head-to-head comparison with the best current treatments in a controlled trial.
• Long-term safety of repeated collagen hydrogel injections into human joints is unknown.
• The optimal dose and injection interval for human OA has not been determined.
• Whether the effect varies with age, OA severity, joint location (knee vs hip vs hand), or weight is not addressed.

The headline risk here is oversimplification. Several media outlets described the study as showing the drug "reverses" osteoarthritis. What the study shows is a shift toward repair-associated protein production in cells, and a reduction in cartilage loss in an animal model. "Promising preclinical signal" is accurate. "Reversal" implies macroscopic cartilage regrowth in humans, which has not been demonstrated.

FAQ

Source(s): ScienceDaily / Yale School of Medicine, via Bioactive Materials (2026)

About the author

Dao Huy (Lucas) is a professional translator working across English, Vietnamese, Chinese, and French, with over seven years of experience in technical, medical, and legal translation. He follows frontier science and medical research out of genuine curiosity and writes plain-language explainers because clear communication about health topics directly affects decisions real people make. When biology reveals something worth knowing, translation between disciplines matters as much as translation between languages.

Lucas offers English-Vietnamese medical and technical translation for clinics, researchers, and health organizations. If you need accurate, context-aware translation for a health or science project, feel free to reach out for a quote.